SCHEMBL5337318

SCHEMBL5337318

COc1cc2oc(=O)cc(O)c2cc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 4/20 0.54
CA12 O43570 3/20 0.54
CA1 P00915 3/20 0.54
CA9 Q16790 3/20 0.54
AKR1B1 P15121 3/20 0.54
CA7 P43166 2/20 0.54
CA13 Q8N1Q1 2/20 0.54
NQO1 P15559 1/20 0.54
ALDH1A1 P00352 10/20 0.53
KDM4E B2RXH2 9/20 0.53
KMT2A Q03164 6/20 0.53
HPGD P15428 6/20 0.53
HSD17B10 Q99714 6/20 0.53
MEN1 O00255 5/20 0.53
GLA P06280 3/20 0.53
GAA P10253 3/20 0.53
CASP1 P29466 2/20 0.53
CASP7 P55210 2/20 0.53
RECQL P46063 2/20 0.53
CYP1A2 P05177 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27903498 0.91 ALDH1A1 (0.59) MCL1CA12CA1CA9AKR1B1
SCHEMBL11845819 0.88 KDM4E (0.51) MCL1CA12CA1CA9AKR1B1
SCHEMBL23117748 0.87 ALDH1A1 (0.46) MCL1CA12CA1CA9AKR1B1
SCHEMBL24753993 0.87 PIM1 (0.51) MCL1CA12CA1CA9AKR1B1
SCHEMBL5088684 0.87 MCL1 (0.53) MCL1CA12CA1CA9AKR1B1
SCHEMBL11855333 0.85 MCL1 (0.54) MCL1CA12CA1CA9AKR1B1
SCHEMBL11844770 0.82 HSD17B3 (0.51) MCL1CA12CA1CA9AKR1B1
SCHEMBL606446 0.80 KDM4E (0.66) MCL1AKR1B1ALDH1A1KDM4EKMT2A
SCHEMBL30819091 0.80 KDM4E (0.66) MCL1AKR1B1ALDH1A1KDM4EKMT2A
SCHEMBL5337634 0.79 CTDSP1 (0.53) MCL1CA12CA1CA9AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102846598-A Application of coumarin in preparing formation inhibitors of advanced glycation end products (AGEs) GUANGZHOU KANGCHENG PHARMACEUTICAL RES CO LTD 2013-01-02 CN disclosed
US-7208518-B2 Substituted furochromene compounds of antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2007-04-24 US disclosed
US-20060148890-A1 Substituted furochromene compounds of antiinflammatory action PLIVA-LSTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed
EP-1648901-A1 SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2006-04-26 EP disclosed
WO-2005010006-A1 SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148890-A1 Substituted furochromene compounds of antiinflammatory action LTC4S, CYP11B2, CYP11B1 MCL1 4672/4885CA12 3303/4885CA1 1868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.